Matt Kaeberlein: Headlines vs the data
🟢
Peer-Reviewed Research
Peer-Reviewed Research
M
Matt Kaeberlein
Video Summary · March 31, 2026
Key Takeaways
- Be cautious when interpreting press releases: the Gallerie Grail trial headlines highlighted positive outcomes but failed its primary endpoint.
- Always verify trial results beyond press releases, as they may focus on secondary outcomes rather than the main goal.
- Monitor stock reactions to trial results as an indicator of market perception, e.g., Gallerie Grail’s stock dropped ~50% after the trial’s failure.
Bottom Line
Scrutinize trial results beyond headlines and press releases to assess their true effectiveness and reliability.
Explore More
- Matt Kaeberlein’s Full Protocol — supplements, dosages, and daily routine
- Compare All Protocols — side-by-side protocols
Watch the Full Video
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.
⚡ Research Insider Weekly
Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.
No spam. Unsubscribe anytime. Powered by Beehiiv.
Related Research
- Rhonda Patrick: Scientists Discovered the Best Type of Exercise for Longevity & Brain Health (this is it)
- Dr. Karan: Supplements ARE Chemicals (And They Affect Your Liver)
- Ben Greenfield: The NAD Mistake 99% of Biohackers Make (Molecular Biologist Explains)
- Rhonda Patrick: If You're Over 40 and Stiff, You Need to See This
From Our Research Network
Healthspan.click
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Daily longevity researchZone2 Training
Exercise protocolsSleep Science
Sleep optimization
Part of the Evidence-Based Research Network